BioRestorative Therapies, Inc.

BRTX • Biotechnology

$0.15

▲ +0.00 (+2.99%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$1.33M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez débil · 0.84Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 14 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 3 sept 2026, 12:17 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.15

Change2.99%

Shares Out8.99M

Market Cap$1.33M

Enterprise Value$-2.26M

52W Range0.16 - 1.73

Beta0.74

P/E-0.12

P/S3.72

P/B0.44

P/FCF-0.11

EV/Sales-6.32

Price$0.15

Change2.99%

Shares Out8.99M

Market Cap$1.33M

Enterprise Value$-2.26M

52W Range0.16 - 1.73

Beta0.74

P/E-0.12

P/S3.72

P/B0.44

P/FCF-0.11

EV/Sales-6.32

EV/EBITDA0.17

EV/FCF0.19

Earnings Yield-830.71%

FCF Yield-893.90%

Dividend Yield0.47%

Gross Margin93.37%

Oper. Margin-43.50%

Profit Margin-39.59%

Debt/Eq0.00

Current Ratio0.84

Quick Ratio0.84

Volume123.44K

Avg Volume7.26M

EPS Surprise0.11

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

32/100

Potencial de crecimiento

Ingresos y expansión

28/100

Atractivo del precio

Barata o cara hoy

20/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez débil · 0.84Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

BRTX

Analyst sentiment

Based on 3 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 12/5/2012

Industria: Biotechnology

P/B i: 0.44

Deuda / Patrimonio i: 0.00

Margen operativo: -4350.05%

Margen neto: -3959.40%

ROE i: -

ROIC: -

Salud financiera

Puntaje6 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 0.84

Ratio rápido: 0.84

Estado: Weak

Advertencias

Weak Liquidity

Transacciones internas

Actividad reciente de ejecutivos e insiders

Randhawa Esha

Transacción: 07/13/2026

OTRO

Cambio

Precio

Not reported

Presentación

07/30/2026

Tipo

OTRO

Dhaliwal Jatinder

Transacción: 06/10/2026

OTRO

Cambio

Precio

Not reported

Presentación

06/18/2026

Tipo

OTRO

Grasso Mika

Transacción: 06/10/2026

OTRO

Cambio

Precio

Not reported

Presentación

06/18/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Randhawa Esha	OTRO	0	Not reported	07/13/2026	07/30/2026
Dhaliwal Jatinder	OTRO	0	Not reported	06/10/2026	06/18/2026
Grasso Mika	OTRO	0	Not reported	06/10/2026	06/18/2026
Field Katharyn	OTRO	0	Not reported	06/10/2026	06/17/2026
ALSTODT LANCE	COMPRA	+11,719	$2.75	10/06/2025	10/20/2025
ALSTODT LANCE	COMPRA	+15,625	$1.60	10/06/2025	10/20/2025
Silva Francisco	COMPRA	+11,719	$2.75	10/06/2025	10/20/2025
Silva Francisco	COMPRA	+11,719	$1.60	10/06/2025	10/20/2025
ALSTODT LANCE	COMPRA	+791,885	$2.46	02/14/2025	02/19/2025
Silva Francisco	COMPRA	+768,979	$2.46	02/14/2025	02/19/2025
Kristal Robert Eugene	COMPRA	+166,492	$2.46	02/14/2025	02/19/2025
Kukekov Nickolay V.	COMPRA	+52,632	$2.46	02/14/2025	02/19/2025
Williams Patrick F.	COMPRA	+52,632	$2.46	02/14/2025	02/19/2025
Rosa David A	COMPRA	+52,632	$2.46	02/14/2025	02/19/2025
Broadrick Dale	VENTA	-1,112	$1.58	10/28/2024	11/05/2024
Silva Francisco	COMPRA	+6,600	$1.25	04/09/2024	04/10/2024
Silva Francisco	COMPRA	+476	$1.13	04/08/2024	04/10/2024
ALSTODT LANCE	VENTA	-17,633	$1.39	03/18/2024	03/20/2024
Silva Francisco	VENTA	-17,193	$1.39	03/18/2024	03/20/2024
ALSTODT LANCE	COMPRA	+438,596	$1.45	02/13/2024	02/15/2024

Sobre la compañía

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.

Fuente - Link

Competidores

BOLT COCP DWTX EDSA EVGN IMNN IMRN MRKR SNSE TRAW

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

BioRestorative Therapies Announces Reverse Stock Split

MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705. The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

GlobeNewsWire

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and underscoring the strength of the Company's vertically integrated regenerative medicine platform.

GlobeNewsWire

BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the appointment of Zachary Smith as Vice President of its Biocosmeceuticals Division, further strengthening the Company's commercial leadership team as it expands its presence within the regenerative aesthetics and advanced skincare market.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.3	-0.19	0.11
2026-03-26	-0.37	-0.37	0
2025-11-12	-0.36	-0.33	0.03
2025-08-12	-0.41	-0.3	0.11
2025-05-14	-0.32	-0.56	-0.24
2025-03-27	-0.27	-0.2	0.07
2024-11-12	-0.43	-0.13	0.3
2024-08-13	-0.56	-0.5	0.06
2024-06-11	-0.51	-0.33	0.18
2024-03-29	-0.65	-0.57	0.08
2023-11-13	-0.68	-0.64	0.04
2023-08-11	-1.19	-0.77	0.42